Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 108-118

  Martinez Quintanilla, Jordi ^a   He, Derek ^a   Wakimoto, Hiroaki ^a   Alemany, Ramon ^b   Shah, Khalid ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; HYALURONIDASE; BIOMIMETIC MATERIAL; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; VIRAL PROTEIN;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL ENCAPSULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EMBRYO; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TUMOR GROWTH; ADENOVIRIDAE; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; CYTOLOGY; DRUG SCREENING; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; INTRALESIONAL DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; TUMOR CELL LINE; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

ADENOVIRIDAE; ANIMALS; BIOMIMETIC MATERIALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLIOBLASTOMA; HEK293 CELLS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; INJECTIONS, INTRALESIONAL; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; SURVIVAL ANALYSIS; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920652460     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.204     Document Type: Article

References (50)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Alonso, MM, Cascallo, M, Gomez-Manzano, C, Jiang, H, Bekele, BN, Perez-Gimenez, A et al. (2007). ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 67: 8255-8263.
3. Parker, JN, Bauer, DF, Cody, JJ and Markert, JM (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
4. Chiocca, EA, Abbed, KM, Tatter, S, Louis, DN, Hochberg, FH, Barker, F et al. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958-966.
5. Chiocca, EA, Smith, KM, McKinney, B, Palmer, CA, Rosenfeld, S, Lillehei, K et al. (2008). A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16: 618-626.
6. Lang, FF, Bruner, JM, Fuller, GN, Aldape, K, Prados, MD, Chang, S et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508-2518.
7. Sironen, RK, Tammi, M, Tammi, R, Auvinen, PK, Anttila, M and Kosma, VM (2011). Hyaluronan in human malignancies. Exp Cell Res 317: 383-391.
8. Park, JB, Kwak, HJ and Lee, SH (2008). Role of hyaluronan in glioma invasion. Cell Adh Migr 2: 202-207.
9. Guedan, S, Rojas, JJ, Gros, A, Mercade, E, Cascallo, M and Alemany, R (2010). Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18: 1275-1283.
10. Shuster, S, Frost, GI, Csoka, AB, Formby, B and Stern, R (2002). Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 102: 192-197.
11. Wakimoto, H, Mohapatra, G, Kanai, R, Curry, WT Jr, Yip, S, Nitta, M et al. (2012). Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 14: 132-144.
12. Wakimoto, H, Kesari, S, Farrell, CJ, Curry, WT Jr, Zaupa, C, Aghi, M et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481.
13. Smith, TT, Roth, JC, Friedman, GK and Gillespie, GY (2014). Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother 2014: 21-33.
14. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
15. Mohyeldin, A and Chiocca, EA (2012). Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J 18: 82-88.
16. Kaur, B, Chiocca, EA and Cripe, TP (2012). Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 13: 1842-1851.
17. Ahmed, AU, Thaci, B, Alexiades, NG, Han, Y, Qian, S, Liu, F et al. (2011). Neural stem cell-based cell carriers enhance therapeutic effcacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 19: 1714-1726.
18. Ma, W, Fitzgerald, W, Liu, QY, O'Shaughnessy, TJ, Maric, D, Lin, HJ et al. (2004). CNS stem and progenitor cell differentiation into functional neuronal circuits in three-dimensional collagen gels. Exp Neurol 190: 276-288.
19. Potter, W, Kalil, RE and Kao, WJ (2008). Biomimetic material systems for neural progenitor cell-based therapy. Front Biosci 13: 806-821.
20. Hansen, K, Müller, FJ, Messing, M, Zeigler, F, Loring, JF, Lamszus, K et al. (2010). A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells. Neuro Oncol 12: 645-654.
21. Prestwich, GD (2011). Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 155: 193-199.
22. Kauer, TM, Figueiredo, JL, Hingtgen, S and Shah, K (2012). Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 15: 197-204.
23. Duebgen, M, Martinez-Quintanilla, J, Tamura, K, Hingtgen, S, Redjal, N, Wakimoto, H et al. (2014). Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst 106: dju090.
24. Stuckey, DW, Hingtgen, SD, Karakas, N, Rich, BE, and Shah, K (2014). Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells (epub ahead of print)
25. Pluen, A, Boucher, Y, Ramanujan, S, McKee, TD, Gohongi, T, di Tomaso, E et al. (2001). Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98: 4628-4633.
26. Pedron, S, Becka, E and Harley, BA (2013). Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid. Biomaterials 34: 7408-7417.
27. Maria, BL, Gupta, N, Gilg, AG, Abdel-Wahab, M, Leonard, AP, Slomiany, M et al. (2008). Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas. J Child Neurol 23: 1214-1220.
28. Kuriyama, N, Kuriyama, H, Julin, CM, Lamborn, K and Israel, MA (2000). Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 11: 2219-2230.
29. McKee, TD, Grandi, P, Mok, W, Alexandrakis, G, Insin, N, Zimmer, JP et al. (2006). Degradation of fbrillar collagen in a human melanoma xenograft improves the effcacy of an oncolytic herpes simplex virus vector. Cancer Res 66: 2509-2513.
30. Ganesh, S, Gonzalez-Edick, M, Gibbons, D, Van Roey, M and Jooss, K (2008). Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 14: 3933-3941.
31. Mok, W, Boucher, Y and Jain, RK (2007). Matrix metalloproteinases-1 and-8 improve the distribution and effcacy of an oncolytic virus. Cancer Res 67: 10664-10668.
32. Thaci, B, Ulasov, IV, Ahmed, AU, Ferguson, SD, Han, Y and Lesniak, MS (2013). Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther 20: 318-327.
33. Jin, SG, Jeong, YI, Jung, S, Ryu, HH, Jin, YH and Kim, IY (2009). The effect of hyaluronic Acid on the invasiveness of malignant glioma cells: comparison of invasion potential at hyaluronic Acid hydrogel and matrigel. J Korean Neurosurg Soc 46: 472-478.
34. Boregowda, RK, Appaiah, HN, Siddaiah, M, Kumarswamy, SB, Sunila, S, Thimmaiah, KN et al. (2006). Expression of hyaluronan in human tumor progression. J Carcinog 5: 2.
35. Toole, BP (2004). Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539.
36. Kim, MS, Park, MJ, Moon, EJ, Kim, SJ, Lee, CH, Yoo, H et al. (2005). Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res 65: 686-691.
37. Shah, K, Bureau, E, Kim, DE, Yang, K, Tang, Y, Weissleder, R et al. (2005). Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 57: 34-41.
38. Kranzler, J, Tyler, MA, Sonabend, AM, Ulasov, IV and Lesniak, MS (2009). Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Curr Gene Ther 9: 389-395.
39. Ahmed, AU, Thaci, B, Tobias, AL, Auffnger, B, Zhang, L, Cheng, Y et al. (2013). A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 105: 968-977.
40. Lee, DH, Ahn, Y, Kim, SU, Wang, KC, Cho, BK, Phi, JH et al. (2009). Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15: 4925-4934.
41. Abumaree, M, Al Jumah, M, Pace, RA and Kalionis, B (2012). Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 8: 375-392.
42. Kanai, R, Rabkin, SD, Yip, S, Sgubin, D, Zaupa, CM, Hirose, Y et al. (2012). Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 104: 42-55.
43. Baumgartner, G (1998). The impact of extracellular matrix on chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 131: 1-2.
44. Shah, K (2012). Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 64: 739-748.
45. Somoza, RA and Rubio, FJ (2012). Cell therapy using induced pluripotent stem cells or somatic stem cells: this is the question. Curr Stem Cell Res Ther 7: 191-196.
46. Rojas, JJ, Guedan, S, Searle, P F, Martinez-Quintanilla, J, Gil-Hoyos, R, Alcayaga-Miranda, F et al. (2010). Minimal RB-responsive E1A promoter modifcation to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 18: 1960-1971.
47. Cascallo, M, Gros, A, Bayo, N, Serrano, T, Capella, G and Alemany, R (2006). Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 17: 929-940.
48. Martinez-Quintanilla, J, Bhere, D, Heidari, P, He, D, Mahmood, U and Shah, K (2013). Therapeutic effcacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells 31: 1706-1714.
49. Sasportas, LS, Kasmieh, R, Wakimoto, H, Hingtgen, S, van de Water, JA, Mohapatra, G et al. (2009). Assessment of therapeutic effcacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827.
50. Hingtgen, S, Figueiredo, JL, Farrar, C, Duebgen, M, Martinez-Quintanilla, J, Bhere, D et al. (2013). Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J Neurooncol 111: 153-161.